A detailed history of Bi Asset Management Fondsmaeglerselskab A transactions in United Therapeutics Corp stock. As of the latest transaction made, Bi Asset Management Fondsmaeglerselskab A holds 70,278 shares of UTHR stock, worth $25.3 Million. This represents 0.44% of its overall portfolio holdings.

Number of Shares
70,278
Previous 75,669 7.12%
Holding current value
$25.3 Million
Previous $24.1 Million 4.48%
% of portfolio
0.44%
Previous 0.39%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

SELL
$311.04 - $363.55 $1.68 Million - $1.96 Million
-5,391 Reduced 7.12%
70,278 $25.2 Million
Q2 2024

Aug 14, 2024

BUY
$228.26 - $319.04 $11.7 Million - $16.3 Million
51,096 Added 207.94%
75,669 $24.1 Million
Q1 2024

May 03, 2024

BUY
$210.76 - $249.51 $1.41 Million - $1.67 Million
6,708 Added 37.55%
24,573 $5.65 Million
Q4 2023

Feb 09, 2024

BUY
$214.88 - $256.94 $3.01 Million - $3.59 Million
13,988 Added 360.79%
17,865 $3.93 Million
Q3 2023

Nov 13, 2023

BUY
$211.82 - $248.24 $625,928 - $733,549
2,955 Added 320.5%
3,877 $876,000
Q2 2023

Aug 03, 2023

SELL
$205.19 - $232.99 $488,352 - $554,516
-2,380 Reduced 72.08%
922 $204,000
Q1 2023

May 12, 2023

BUY
$212.99 - $276.17 $471,985 - $611,992
2,216 Added 204.05%
3,302 $740,000
Q4 2022

Feb 13, 2023

BUY
$205.95 - $280.43 $223,661 - $304,546
1,086 New
1,086 $302,000
Q2 2022

Aug 12, 2022

BUY
$174.81 - $241.14 $154,532 - $213,167
884 New
884 $208,000
Q2 2019

Mar 19, 2020

SELL
$76.06 - $120.81 $76,060 - $120,810
-1,000 Closed
0 $0
Q1 2019

Mar 19, 2020

SELL
$107.15 - $126.84 $139,295 - $164,892
-1,300 Reduced 56.52%
1,000 $117,000
Q4 2018

Mar 19, 2020

BUY
$101.4 - $128.73 $233,220 - $296,079
2,300 New
2,300 $250,000

Others Institutions Holding UTHR

About UNITED THERAPEUTICS Corp


  • Ticker UTHR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 45,516,300
  • Market Cap $16.4B
  • Description
  • United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. Its commercial therapies include Remodulin to treat patients with pulmonary arterial hypertensio...
More about UTHR
Track This Portfolio

Track Bi Asset Management Fondsmaeglerselskab A Portfolio

Follow Bi Asset Management Fondsmaeglerselskab A and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Bi Asset Management Fondsmaeglerselskab A, based on Form 13F filings with the SEC.

News

Stay updated on Bi Asset Management Fondsmaeglerselskab A with notifications on news.